Advisor Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Advisor Group’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$3K	Buy	+2,000	New	+$1.73K	﹤0.01%	4933
2019 Q2	–	Sell	-25	Closed	–	–	5530
2019 Q1	$0	Sell	25 -75	-75%	-$221	﹤0.01%	5439
2018 Q4	$0	Hold	100	–	–	﹤0.01%	5366
2018 Q3	$0	Hold	100	–	–	﹤0.01%	5334
2018 Q2	$0	Hold	100	–	–	﹤0.01%	5147
2018 Q1	$1K	Sell	100 -75	-43%	-$561	﹤0.01%	4901
2017 Q4	$2K	Hold	175	–	–	﹤0.01%	4755
2017 Q3	$2K	Hold	175	–	–	﹤0.01%	4611
2017 Q2	$2K	Hold	175	–	–	﹤0.01%	4565
2017 Q1	$2K	Hold	175	–	–	﹤0.01%	4456
2016 Q4	$2K	Buy	175 +75	+75%	+$1.19K	﹤0.01%	4288
2016 Q3	$2K	Hold	100	–	–	﹤0.01%	4234
2016 Q2	$1K	Buy	+100	New	+$1.96K	﹤0.01%	4330

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $305M AUM 26.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

PFO

Pathstone Family Office Englewood, New Jersey $13.1B AUM 20.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisor Group's NAVB Position: Q4 2019 in Review

Advisor Group opened a new position in Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2019: 2,000 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #4933 among its holdings. This is a return to the name: Advisor Group previously reported a position in NAVB as recently as Q1 2019.

Advisor Group first reported a position in NAVB in Q2 2016 and has held it in 13 quarters since. 28 funds tracked by Wall St. Rank hold NAVB as of Q4 2019.

Advisor Group held 2,000 shares of Navidea Biopharmaceuticals Inc. worth $3K as of Q4 2019.
Navidea Biopharmaceuticals Inc. was a new Advisor Group position in Q4 2019.
Navidea Biopharmaceuticals Inc. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4933 holding.
Advisor Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2016 and has held it in 13 quarters since.
28 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.